Psychedelic therapy is promising in the depression study resistant to treatment

Experimental psychedelic therapy of the British company Beckley Psytech has considerably reduced the symptoms of depression resistant to treatment in a mid-term test, according to recently published data, which increases the expectations of a class of drugs which are directed towards potential approval by American regulators.

Companies like Beckley, Atai Life Sciences and Compass Pathways – the first two are merging – are now in the running to put psychedelic therapies on the market at a time when the regulatory and political climate seems to change. The industry has the support of the members of the two parties, and several psychedelic user -friendly characters have been appointed to political posts under the Secretary of Health, Robert F. Kennedy, Jr.

In a phase 2B clinical trial, the compound of Beckley, BPL -003 – an intranasal formulation of mebufotenine, a short -acting compound linked to psychedelic DMT – led to a reduction of 12.1 and 11.1 points on a standard clinical measure of depression called the Madrs scale on day 29, depending on the dose. This is compared to a reduction of 5.8 of the low -dose comparison group, taking into account the primary secondary and key assessment criteria. There were 193 participants in the study.